Melatonin

Property	Information
Drug Name	Melatonin
FDA Approval	No
Used for	Glioblastoma Multiforme (GBM), insomnia, jet lag
Clinical Trial Phase	Mixed (Phase 2 and Phase 3 trials mentioned)
Clinical Trial Explanation	Not specified
Common Side Effects	No known toxic side effects
OS without	Survival significantly greater in melatonin-treated subjects in small GBM study
OS with	Increases efficacy of chemotherapy; significant survival benefit observed in various cancers
PFS without	Not specified
PFS with	Not specified
Usefulness Rating	4
Usefulness Explanation	Not specified
Toxicity Level	3
Toxicity Explanation	Not specified

Notes: Melatonin has shown promise in clinical trials, primarily in Italy, used both as a single agent and in combination with chemotherapy or immunotherapy. Significant increases in survival rates have been observed in trials for GBM, lung cancer, and other cancers. Melatonin not only increased the efficacy of chemotherapy but also significantly reduced its toxicity.

Links: * [Link to study on Melatonin and GBM](https://pubmed.ncbi.nlm.nih.gov/35395355)

• [Link to review on therapeutic strategies for GBM](#)
• [Link to clinical trial results of Melatonin use in cancer treatment](#)

From Ben Williams Book: Not specified

Loading comments...